The place of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Panic disorder is a frequently chronic condition with extensive patterns of psychiatric comorbidity. Optimum pharmacotherapy with traditional agents is limited by side effects, long-term tolerability, and other problems. Recent research findings support the characterization of panic disorder as an illness involving derangements of central serotonergic function. Selective serotonin reuptake inhibitors could become first-line treatment of the disorder, as they seem to have fewer side effects than tricyclic antidepressants and benzodiazepines.
DeVane
C L
CL
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425-0742, USA.
D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D006801:Humans; D016584:Panic Disorder / Q000503:physiopathology / Q000628:therapy*; D012701:Serotonin / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors